Introduction Triple-negative breast cancer (TNBC) accounts for approximately 10%-15% of
all diagnosed breast cancers and is associated with an aggressive natural history and poor …

Atezolizumab (Tecentriq®), an immune checkpoint inhibitor against programmed death
ligand 1 (PD-L1), is the first immunotherapy agent to be approved (for use in combination …

Introduction: Breast cancer is the most common malignancy in women in the United States
and triple-negative breast cancer (TNBC) accounts for 15–20%. The standard of care for …

Introduction: Triple-negative breast cancer (TNBC) is associated with poor prognosis and
limited treatment options. However, TNBC is known to be more immunogenic compared to …

Background: Triple-negative breast cancer (TNBC) represents an aggressive breast cancer
subtype with historically poor overall outcomes, due primarily to a lack of effective targeted …

Importance Atezolizumab (anti–programmed cell death ligand 1 [PD-L1]) is well tolerated
and clinically active in multiple cancer types. Its safety and clinical activity in metastatic triple …

Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast
cancer (mTNBC) but only for PD-L1positive disease. The randomized, placebo-controlled …

Background Immunotherapy with checkpoint inhibitors (CI) represents an important novel
development in cancer treatment. Metastatic triple-negative breast cancer (mTNBC) is …

Importance The humanized monoclonal antibody atezolizumab targets programmed death-
ligand 1 and has demonstrated durable single-agent activity in a subset of metastatic triple …

TPS1104 Background: Treatment for mTNBC is limited, with chemotherapy the mainstay
(bevacizumab is approved in> 80 countries). Atezolizumab (atezo; MPDL3280A), a …